Agendia Highlights Study Showing MammaPrint/BluePrint Tests Predict Response to Current Breast Cancer Chemotherapy and Targeted Therapy Regimens
Researchers present data at breast cancer symposium showing MammaPrint/BluePrint can identify women who benefit from chemotherapy and targeted dual anti-HER2 drug treatment before surgery